Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Last trade$5.43
Day change-$0.38 (-6.54%)
Day range$5.36 – $6.10
Volume1,245,928
Market cap$456M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$455.77M
Price / earnings
—
Price / book
3.46×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.71×
Profitability
Earnings per share
-$1.26
Return on assets
-46.96%
Return on equity
-75.34%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.37×
Current ratio
7.57×
Quick ratio
7.57×
Cash ratio
7.42×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$70.2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CADL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$7.39M
$6.95M
$6.44M
$4.72M
$4.75M
$4.19M
$4.11M
$3.32M
Research and development
$15.59M
$19.8M
$9.84M
$11.03M
$8.46M
$6.99M
$4.02M
$4.82M
Total operating expenses
$22.98M
$26.75M
$16.28M
$15.75M
$13.21M
$11.18M
$8.13M
$8.14M
Operating income
-$22.98M
-$26.75M
-$16.28M
-$15.75M
-$13.21M
-$11.18M
-$8.13M
-$8.14M
Interest expense
-$1.59M
-$1.58M
-$1.56M
-$1.42M
-$161K
-$236K
-$306K
-$390K
Income before taxes
-$21.87M
-$38.93M
-$8.86M
-$29.5M
-$11.27M
-$4.8M
$7.38M
-$14.07M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$21.87M
-$38.93M
-$8.86M
-$29.5M
-$11.27M
-$4.8M
$7.38M
-$14.07M
Net income attributable to common shareholders
-$21.87M
-$38.91M
-$8.86M
-$29.5M
-$11.27M
-$4.8M
$7.38M
-$14.07M
EBITDA
-$22.81M
-$26.58M
-$16.14M
-$15.59M
-$13.01M
-$10.94M
-$7.89M
-$7.9M
Basic earnings per share
-$0.28
-$0.52
-$0.14
-$0.54
-$0.21
-$0.09
$0.15
-$0.40
Diluted earnings per share
-$0.28
-$0.52
-$0.14
-$0.58
-$0.21
-$0.09
$0.13
-$0.40
Recent news
Company coverage with links to the original publishers.
Candel Therapeutics announced that its phase 2 PrTK05 clinical trial data for aglatimagene besadenovec in localized prostate cancer has been accepted for poster presentation at the SITC 41st Annual Meeting in November 2026. The presentation will feature longitudinal immune-profiling, biodistribution, and viral shedding data from the trial combining aglatimagene with valacyclovir and radiation therapy.
Candel Therapeutics announced that it will present data from its aglatimagene besadenovec program in non-small cell lung cancer and clinical findings from its phase 1b trial of linoserpaturev in recurrent glioblastoma at the Society for Immunotherapy of Cancer's 41st Annual Meeting in November 2026. The presentations will showcase multi-omics analyses revealing immune activation and improved survival outcomes.
As prostate cancer incidence rises with advanced-stage diagnoses increasing, four pharmaceutical companies are advancing treatments. Pfizer and Novartis, with established prostate cancer franchises, await FDA decisions on label expansions for Talzenna/Xtandi and Pluvicto respectively. Candel and Janux, earlier-stage developers, are preparing regulatory filings and advancing clinical programs in this growing market.
U.S. stock futures rose on Friday ahead of Q4 GDP data and PCE inflation gauge releases. Markets are pricing in a 94% likelihood of unchanged Fed rates in March. Notable movers include Copart missing earnings expectations, Comfort Systems raising dividends, Grail plunging 47% on weak earnings, Candel Therapeutics declining on stock offering announcement, and Dropbox falling despite beating earnings. Wells Fargo strategist recommends leaning into growth-sensitive sectors like Financials and Industrials rather than defensive positioning.
Candel Therapeutics announced a public offering of 18.3 million shares at $5.45 per share, raising $100 million in gross proceeds. The company plans to use the funds for launch readiness and commercialization of aglatimagene besadenovec for localized prostate cancer, ongoing phase 3 trials in non-small cell lung cancer, and general corporate purposes. The offering is expected to close on February 23, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.